InvestorsHub Logo
Followers 4
Posts 142
Boards Moderated 0
Alias Born 07/11/2011

Re: vip1999 post# 2522

Sunday, 07/26/2015 5:50:43 PM

Sunday, July 26, 2015 5:50:43 PM

Post# of 4493
"Our two pivotal clinical trials with evofosfamide remain on track," said Barry Selick, Ph.D., Chief Executive Officer of Threshold. "Based on current projections, we expect that the number of protocol-specified events for the pivotal Phase 3 trials of evofosfamide in patients with advanced soft tissue sarcoma as well as in patients with advanced pancreatic cancer (MAESTRO) may be reached in the second half of 2015, with the results of the primary efficacy analyses to be available shortly thereafter.

You can read the complete press release here.

-null

Disclaimer: Everything is just my opinion. Please do your own due diligence.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MTEM News